Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

~ This is the second IND Clearance over the last 100 days for drug candidates that are being developed using guidance from Lantern’s AI Platform, RADR®. ~ LP-284 is the second of Lantern’s synthetic-lethal franchise of molecules that have shown to be synthetically lethal in DNA damage repair deficient cancers and are entering into first-in-human clinical trials. ~ Lantern estimates that LP-284 can have the potential to improve outcomes for 40,000 to 80,000 patients with blood cancers annually, with a global annual market potential of $4 Billion USD.

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here